AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22386472 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg duloxetine once per day (Study 1)
Number of subjects: 404
Study 22386472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 20201945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated Escherichia Coli Asparaginase (Peg‐ASP) 1000 units/m(2) with concurrent heparin prophylaxis
Number of subjects: 1824
Study 20201945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated Escherichia Coli Asparaginase (Peg‐ASP) 1000 units/m(2)
Number of subjects: 1824
Study 20201945 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-exposure to Asparaginase
Number of subjects: 1824
Study 17661342 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally oriented intervention delivered on 3 occasions over 9 to 12 weeks
Number of subjects: 60
Study 17661342 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally oriented intervention
Number of subjects: 60
Study 17661342 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 60
Study 15569860 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 2 mg, vitamin B12 0.5 mg, and vitamin B6 25 mg
Number of subjects: 285
Study 15569860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 12101076 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dexamethasone therapy
Number of subjects: 20
Study 12101076 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 20
Study 10189536 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I at a dose of 40/40 micrograms/kg
Number of subjects: 223
Study 10189536 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I at a dose of 80/40 micrograms/kg
Number of subjects: 223
Study 10189536 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I at a dose of 80/60 micrograms/kg
Number of subjects: 223
Study 10189536 — intervention group
Group type: COMPARATOR
Intervention: Intensified insulin therapy alone (placebo)
Number of subjects: 223
Study 10189536 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I/insulin cotherapy
Number of subjects: 223
Study 10189536 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 223
Study 10189536 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of rhIGF‐I
Number of subjects: 223
Study 7772362 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA with midazolam-alfentanil reversed with flumazenil (Group 1)
Number of subjects: 80
Study 7772362 — intervention group
Group type: COMPARATOR
Intervention: TIVA with midazolam-alfentanil without reversal (Group 2)
Number of subjects: 80
Study 7772362 — intervention group
Group type: COMPARATOR
Intervention: Neurolept anesthesia with thiopental sodium, droperidol, fentanyl, and N2O (Group 3)
Number of subjects: 80
Study 7772362 — intervention group
Group type: COMPARATOR
Intervention: Neurolept anesthesia (Group 3)
Number of subjects: 80
Study 7772362 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 2271083 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (low-dose azathioprine, cyclosporin, methylprednisolone) continued (group A)
Number of subjects: 128
Study 2271083 — intervention group
Group type: EXPERIMENTAL
Intervention: Aza and CyA (group B)
Number of subjects: 128
Study 2271083 — intervention group
Group type: EXPERIMENTAL
Intervention: Aza and MP (group C)
Number of subjects: 128
Study 2271083 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA and MP (group D)
Number of subjects: 128
Study 2271083 — intervention group
Group type: COMPARATOR
Intervention: Graft survival rates
Number of subjects: 128
Study 2271083 — intervention group
Group type: COMPARATOR
Intervention: Patient survival rates
Number of subjects: 128
Study 76398 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% podophyllin
Number of subjects: 227
Study 76398 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% podophyllotoxin
Number of subjects: 227
Study 76398 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% colchicine
Number of subjects: 227
Study 76398 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 227
Study 31633262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructans (40g)
Number of subjects: 20
Study 31633262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (40g)
Number of subjects: 20
Study 31633262 — intervention group
Group type: COMPARATOR
Intervention: Glucose (as placebo)
Number of subjects: 20
Study 31894036 — intervention group
Group type: COMPARATOR
Intervention: Low-dose alteplase (0.6 mg/kg)
Number of subjects: 86
Study 31894036 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose alteplase (0.9 mg/kg)
Number of subjects: 86
Study 27492741 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive intracutaneous injections with local anesthetics and steroids
Number of subjects: 93
Study 27492741 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 93
Study 25878175 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 4-12 mg
Number of subjects: 0
Study 25878175 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg
Number of subjects: 0
Study 25878175 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg
Number of subjects: 0
Study 25878175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23151354 — intervention group
Group type: EXPERIMENTAL
Intervention: Two green kiwifruits per day plus healthy diet
Number of subjects: 85
Study 23151354 — intervention group
Group type: COMPARATOR
Intervention: Healthy diet alone
Number of subjects: 85
Study 21899566 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl (30 min) + 17% EDTA (5 min)
Number of subjects: 100
Study 21899566 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 100
Study 21899566 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA (30 min)
Number of subjects: 100
Study 21899566 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% EDTA gel (30 min)
Number of subjects: 100
Study 21899566 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CHX gel (30 min)
Number of subjects: 100
Study 21899566 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl (30 min)
Number of subjects: 100
Study 19014354 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferroxamine infusion for 8 hours
Number of subjects: 15
Study 19014354 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study 19014354 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferroxamine infusion
Number of subjects: 15
Study 17503749 — intervention group
Group type: EXPERIMENTAL
Intervention: DNAaemia
Number of subjects: 200
Study 17503749 — intervention group
Group type: COMPARATOR
Intervention: Antigenaemia
Number of subjects: 200
Study 17503749 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 200
Study 15343531 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus femoral nerve block (FNB) with 30 mL of 0.5% bupivacaine with epinephrine 1:200,000
Number of subjects: 40
Study 15343531 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia plus femoral nerve block (FNB) with 30 mL of preservative-free saline
Number of subjects: 40
Study 11451621 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg/day for 21 days followed by chlormadinone acetate for 5 days
Number of subjects: 25
Study 9511844 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment and prevention program
Number of subjects: 0
Study 9511844 — intervention group
Group type: COMPARATOR
Intervention: Geriatric Oral Health Assessment Index (GOHAI)
Number of subjects: 0
Study 9511844 — intervention group
Group type: COMPARATOR
Intervention: Self-reported need for dental treatment
Number of subjects: 0
Study 7872725 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 19.9 > 37 U/ml
Number of subjects: 150
Study 7872725 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA > 5 ng/ml
Number of subjects: 150
Study 3258994 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation Group
Number of subjects: 20
Study 3258994 — intervention group
Group type: COMPARATOR
Intervention: Voluntary Exercise Group
Number of subjects: 20
Study 29885153 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist model of SBIRT
Number of subjects: 7
Study 29885153 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalist model of SBIRT
Number of subjects: 7
Study 27185699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg (P150)
Number of subjects: 97
Study 27185699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg (P75)
Number of subjects: 97
Study 27185699 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5 mg (D5)
Number of subjects: 97
Study 24725276 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory respiratory training
Number of subjects: 100
Study 24725276 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory respiratory training
Number of subjects: 100
Study 24725276 — intervention group
Group type: COMPARATOR
Intervention: Sham respiratory training
Number of subjects: 100
Study 24725276 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 100
Study 22109683 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution
Number of subjects: 57
Study 22109683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 57
Study 19531931 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSorb-D 12.5 mg
Number of subjects: 53
Study 19531931 — intervention group
Group type: EXPERIMENTAL
Intervention: DPSGC 25 mg
Number of subjects: 53
Study 19531931 — intervention group
Group type: EXPERIMENTAL
Intervention: DPSGC 50 mg
Number of subjects: 53
Study 19531931 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac potassium 50 mg tablet
Number of subjects: 53
Study 18543381 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Qigong (MQ) program for 8 weeks
Number of subjects: 30
Study 18543381 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 30
Study 15967914 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate cream, 40-g/d dosage
Number of subjects: 341
Study 15967914 — intervention group
Group type: COMPARATOR
Intervention: Oral corticosteroids, 0.5 or 1.0 mg/kg per day depending on extent of BP
Number of subjects: 341
Study 12071371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed orthodontic appliances and initial archwire placement
Number of subjects: 18
Study 12071371 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 18
Study 10332663 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (55%)
Number of subjects: 9
Study 10332663 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate diet (40%)
Number of subjects: 9
Study 8738944 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate
Number of subjects: 111
Study 1902410 — intervention group
Group type: EXPERIMENTAL
Intervention: ponalrestat (two 300 mg tablets daily)
Number of subjects: 55
Study 1902410 — intervention group
Group type: COMPARATOR
Intervention: placebo tablets
Number of subjects: 55
Study 6176796 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 15
Study 6176796 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 20 mg
Number of subjects: 15
Study 6176796 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg
Number of subjects: 15
Study 6176796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31189759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-modifying therapy (LT) level I with low HDL-C (＜40 mg/dL for men; ＜50 mg/dL for women)
Number of subjects: 3640
Study 31189759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-modifying therapy (LT) level II with high HDL-C (≥ 40 mg/dL for men; ≥ 50 mg/dL for women)
Number of subjects: 3640
Study 31189759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-modifying therapy (LT) level III with high HDL-C and low triglycerides (＜150 mg/dL)
Number of subjects: 3640
Study 31189759 — intervention group
Group type: COMPARATOR
Intervention: No lipid-modifying therapy (LT) prescribed (level 0)
Number of subjects: 3640
Study 31189759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-modifying therapy (LT) level I
Number of subjects: 3640
Study 31189759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-modifying therapy (LT) level II
Number of subjects: 3640
Study 31189759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-modifying therapy (LT) level III
Number of subjects: 3640
Study 31437816 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 176250
Study 31437816 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP4 inhibitors
Number of subjects: 176250
Study 31437816 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP1 analogs
Number of subjects: 176250
Study 31437816 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 176250
Study 29088237 — intervention group
Group type: EXPERIMENTAL
Intervention: Current weekend allied health service (including physical therapy, occupational therapy, speech therapy, dietetics, social work, and allied health assistant services)
Number of subjects: 14834
Study 29088237 — intervention group
Group type: COMPARATOR
Intervention: No weekend allied health service
Number of subjects: 14834
Study 29088237 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed weekend allied health service
Number of subjects: 14834
Study 25564250 — intervention group
Group type: EXPERIMENTAL
Intervention: EE audio program and discussion guide
Number of subjects: 264
Study 25564250 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 264
Study 24249423 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate (HAL) instillation before surgery with blue-light cystoscopy (BL group)
Number of subjects: 130
Study 24249423 — intervention group
Group type: COMPARATOR
Intervention: White-light cystoscopy (WL group)
Number of subjects: 130
Study 22119997 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care practitioners during pregnancy
Number of subjects: 649
Study 22119997 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care practitioners at school age
Number of subjects: 649
Study 22119997 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents during pregnancy
Number of subjects: 649
Study 22119997 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents at school age
Number of subjects: 649
Study 22119997 — intervention group
Group type: EXPERIMENTAL
Intervention: Friends and relatives at school age
Number of subjects: 649
Study 22119997 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet at school age
Number of subjects: 649
Study 19123151 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol fixed combination (BTFC)
Number of subjects: 82
Study 19123151 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 82
Study 17512721 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFx6 or 7
Number of subjects: 767
Study 17512721 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary amenorrhea
Number of subjects: 767
Study 17512721 — intervention group
Group type: COMPARATOR
Intervention: No CT
Number of subjects: 767
Study 15451336 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol (misoprostol administered 6-8 hours vs. 23-25 hours after mifepristone)
Number of subjects: 931
Study 15451336 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol (when both clinician and patient felt the gestational sac had passed)
Number of subjects: 931
Study 15451336 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol (overall sensitivity, specificity, and predictive values)
Number of subjects: 931
Study 11553119 — intervention group
Group type: EXPERIMENTAL
Intervention: Household cleansing solutions adjusted to pH 7.4
Number of subjects: 30
Study 11553119 — intervention group
Group type: EXPERIMENTAL
Intervention: Household cleansing solutions adjusted to pH 10.0
Number of subjects: 30
Study 11553119 — intervention group
Group type: EXPERIMENTAL
Intervention: Household cleansing solutions adjusted to pH 10.8
Number of subjects: 30
Study 9716580 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microgram/kg BB-10010
Number of subjects: 30
Study 9716580 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microgram/kg BB-10010
Number of subjects: 30
Study 9716580 — intervention group
Group type: COMPARATOR
Intervention: Control (no BB-10010)
Number of subjects: 30
Study 9716580 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-10010 (both dosages)
Number of subjects: 30
Study 9716580 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-10010
Number of subjects: 30
Study 8014642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed low-dose warfarin (2 mg/d)
Number of subjects: 96
Study 8014642 — intervention group
Group type: COMPARATOR
Intervention: Adjusted higher-dose warfarin
Number of subjects: 96
Study 2685260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Partial Dentures (FPDs)
Number of subjects: 232
Study 2685260 — intervention group
Group type: COMPARATOR
Intervention: Removable Partial Dentures (RPDs)
Number of subjects: 232
Study 2685260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Partial Dentures (FPDs) excluding early failures
Number of subjects: 232
Study 2685260 — intervention group
Group type: EXPERIMENTAL
Intervention: Kennedy class II patients with Fixed Partial Dentures (FPDs)
Number of subjects: 232
Study 2685260 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic assessments of implants
Number of subjects: 232
Study 4204541 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin and isoniazid regimen
Number of subjects: 632
Study 4204541 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin, isoniazid, and ethambutol regimen
Number of subjects: 632
Study 4204541 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (streptomycin, isoniazid, and ethambutol)
Number of subjects: 632
Study 31924224 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic exoskeleton over-ground training
Number of subjects: 0
Study 31924224 — intervention group
Group type: COMPARATOR
Intervention: Standard of care walking training (including body-weight supported treadmill training, overground training, stationary robotic systems)
Number of subjects: 0
Study 28543566 — intervention group
Group type: EXPERIMENTAL
Intervention: App
Number of subjects: 220
Study 28543566 — intervention group
Group type: COMPARATOR
Intervention: Booklet
Number of subjects: 220
Study 26481821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg monthly (frequent regimen; n = 102)
Number of subjects: 353
Study 26481821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 or 0.5 mg quarterly (infrequent regimen; n = 217)
Number of subjects: 353
Study 24344871 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading acceleration program
Number of subjects: 97
Study 24344871 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of reading acceleration and WM training
Number of subjects: 97
Study 24344871 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading-acceleration-alone group
Number of subjects: 97
Study 24344871 — intervention group
Group type: EXPERIMENTAL
Intervention: WM-program-followed-by-reading-acceleration group
Number of subjects: 97
Study 24344871 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 22431170 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (anti-androgen)
Number of subjects: 28
Study 22431170 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (GnRH agonist)
Number of subjects: 28
Study 22431170 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 28
Study 22431170 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (Bicalutamide and Goserelin)
Number of subjects: 28
Study 20159209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviorally based self‐help book for tinnitus
Number of subjects: 162
Study 20159209 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 162
Study 18088057 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler sonography (DUS) examination of major abdominal arteries
Number of subjects: 29
Study 15502600 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐MPH
Number of subjects: 132
Study 15502600 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l‐MPH
Number of subjects: 132
Study 15502600 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 132
Study 11170909 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran
Number of subjects: 230
Study 11170909 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin
Number of subjects: 230
Study 11170909 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's
Number of subjects: 230
Study 11170909 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 230
Study 11170909 — intervention group
Group type: COMPARATOR
Intervention: Colloid group (Dextran and Gelatin)
Number of subjects: 230
Study 11170909 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid group (Lactated Ringer's and Normal saline)
Number of subjects: 230
Study 9540946 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg linoleic acid and 600 mg calcium
Number of subjects: 86
Study 9540946 — intervention group
Group type: COMPARATOR
Intervention: 450 mg starch and 600 mg lactose placebo
Number of subjects: 86
Study 8007591 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and chlorambucil (MP+Ch)
Number of subjects: 2
Study 8007591 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (MP)
Number of subjects: 2
Study 8007591 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 2
Study 2689470 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 50 mg
Number of subjects: 117
Study 2689470 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg
Number of subjects: 117